In two subsequent clinical trials (ChiCTR1900025311 and ISRCTN19144142) [55], investigators introduced a novel ‘off-frame’ allogeneic CAR-T-cell therapy, GC027, targeting CD7 in patients with R/R T-ALL. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.